Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL VERTIGO TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL VERTIGO TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL VERTIGO TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH HEMATOLOGISTS
6.8 INTERVIEWS WITH ONCOLOGISTS
6.9 INTERVIEWS WITH CANCER ORGANIZATIONS
6.1 OTHER KOL SNAPSHOTS
7 PIPELINE ANALYSIS
7.1 CLINICAL TRIALS AND PHASE ANALYSIS
7.2 DRUG THERAPY PIPELINE
7.3 PHASE III CANDIDATES
7.4 PHASE II CANDIDATES
7.5 PHASE I CANDIDATES
7.6 OTHERS (PRE-CLINICAL AND RESEARCH)
8 REGULATORY FRAMEWORK
9 GLOBAL VERTIGO TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 PERIPHERAL VERTIGO
9.2.1 BENIGN PAROXYSMAL POSITIONAL VERTIGO (BPPV)
9.2.2 VESTIBULAR NEURONITIS
9.2.3 MÉNIÈRE'S DISEASE
9.2.4 ACOUSTIC NEUROMAS
9.2.5 OTHERS
9.3 CENTRAL VERTIGO
9.3.1 CONCUSSION OR TRAUMATIC BRAIN INJURY
9.3.2 STROKES MAY CAUSE VERTIGO AND LOSS OF COORDINATION.
9.3.3 MULTIPLE SCLEROSIS
9.3.4 TUMORS OF THE BRAIN AND SPINAL CORD
9.3.5 OTHERS
10 GLOBAL VERTIGO TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 PHYSICAL THERAPY
10.2.1 CANALITH REPOSITIONING
10.2.2 BRANDT-DAROFF
10.2.3 SEMONT MANEUVER
10.2.4 LEMPERT MANEUVER
10.2.5 GUFONI MANEUVER
10.2.6 VESTIBULAR REHABILITATION EXERCISES
10.2.7 OTHERS
10.3 PHARMACOLOGICAL TREATMENT
10.3.1 HISTAMINE AGONISTS (BETAHISTINE)
10.3.2 ANTICHOLINERGICS
10.3.2.1. SCOPOLAMINE
10.3.2.2. HYOSCYAMINE
10.3.3 ANTIHISTAMINES
10.3.3.1. MECLIZINE
10.3.3.2. DIMENHYDRINATE
10.3.3.3. PROMETHAZINE
10.3.3.4. CINNARIZINE
10.3.4 BENZODIAZEPINES
10.3.4.1. DIAZEPAM
10.3.4.2. LORAZEPAM
10.3.4.3. CLONAZEPAM
10.3.5 CORTICOSTEROIDS
10.3.5.1. DEXAMETHASONE
10.3.5.2. PREDNISONE
10.3.5.3. METHYLPREDNISOLONE
10.3.6 DOPAMINE ANTAGONIST (METOCLOPRAMIDE)
10.3.7 ANTIEMETIC
10.3.7.1. METACLOPROMIDE
10.3.7.2. PROMETHAZINE
10.3.7.3. ONDANSTERONE
10.3.8 OTHERS
10.3.8.1. ACETYL-LEUCINE
10.3.8.2. GINKGO BILOBA
10.4 SURGERY
10.4.1 ENDOLYMPHATIC SUBARACHNOID SHUNT
10.4.2 RETROLABYRINTHINE VESTIBULAR NEURECTOMY
10.4.3 COCHLEOVESTIBULAR NEURECTOMY
10.4.4 POST AMPULLARY NERVE SECTION
11 GLOBAL VERTIGO TREATMENT MARKET, BY DIAGNOSIS
11.1 OVERVIEW
11.2 FUKUDA-UNTERBERGER’S TEST
11.3 ROMBERG’S TEST
11.4 HEAD IMPULSE TEST
11.5 VESTIBULAR TEST BATTERY
11.6 VIDEONYSTAGMOGRAPHY TESTING
11.7 AUDIOMETRIC TESTS
11.8 OTOACOUSTIC EMISSIONS
11.9 IMAGING TEST
11.9.1 CT
11.9.2 MRI
11.1 OTHERS
12 GLOBAL VERTIGO TREATMENT MARKET, BY DURATION OF EPISODES
12.1 OVERVIEW
12.2 SECONDS
12.3 HOURS
12.4 DAYS
12.5 MONTHS
13 GLOBAL VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE
13.1 OVERVIEW
13.2 OTC
13.3 PRESCRIPTION
14 GLOBAL VERTIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 INJECTABLE
15 GLOBAL VERTIGO TREATMENT MARKET, BY RACE
15.1 OVERVIEW
15.2 CAUCASIAN
15.3 ASIAN
15.4 BLACK
15.5 AUSTRALOID
16 GLOBAL VERTIGO TREATMENT MARKET, BY POPULATION TYPE
16.1 OVERVIEW
16.2 PEDIATRIC
16.3 ADULTS
16.4 GERIATRIC
17 GLOBAL VERTIGO TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 REHABILITATION CENTERS
17.6 OTHERS
18 GLOBAL VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITALS
18.3 RETAIL SALES
18.3.1 ONLINE PHARMACY
18.3.2 RETAIL SHOP
18.4 OTHERS
19 GLOBAL VERTIGO TREATMENT MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.2 COMPANY SHARE ANALYSIS: EUROPE
19.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.4 MERGERS & ACQUISITIONS
19.5 NEW PRODUCT DEVELOPMENT & APPROVALS
19.6 EXPANSIONS
19.7 REGULATORY CHANGES
19.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL VERTIGO TREATMENT MARKET, BY REGION
GLOBAL VERTIGO TREATMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
20.1 NORTH AMERICA
20.1.1 U.S.
20.1.2 CANADA
20.1.3 MEXICO
20.2 EUROPE
20.2.1 GERMANY
20.2.2 FRANCE
20.2.3 U.K.
20.2.4 HUNGARY
20.2.5 LITHUANIA
20.2.6 AUSTRIA
20.2.7 IRELAND
20.2.8 NORWAY
20.2.9 POLAND
20.2.10 ITALY
20.2.11 SPAIN
20.2.12 RUSSIA
20.2.13 TURKEY
20.2.14 NETHERLANDS
20.2.15 SWITZERLAND
20.2.16 REST OF EUROPE
20.3 ASIA-PACIFIC
20.3.1 JAPAN
20.3.2 CHINA
20.3.3 SOUTH KOREA
20.3.4 INDIA
20.3.5 AUSTRALIA
20.3.6 SINGAPORE
20.3.7 THAILAND
20.3.8 MALAYSIA
20.3.9 INDONESIA
20.3.10 PHILIPPINES
20.3.11 VIETNAM
20.3.12 REST OF ASIA-PACIFIC
20.4 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
21 GLOBAL VERTIGO TREATMENT MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL VERTIGO TREATMENT MARKET, COMPANY PROFILE
22.1 SERVICE PROVIDERS
22.1.1 SHEA CLINIC
22.1.1.1. COMPANY OVERVIEW
22.1.1.2. REVENUE ANALYSIS
22.1.1.3. GEOGRAPHIC PRESENCE
22.1.1.4. PRODUCT PORTFOLIO
22.1.1.5. RECENT DEVELOPEMENTS
22.1.2 PRIMUS HOSPITAL
22.1.2.1. COMPANY OVERVIEW
22.1.2.2. REVENUE ANALYSIS
22.1.2.3. GEOGRAPHIC PRESENCE
22.1.2.4. PRODUCT PORTFOLIO
22.1.2.5. RECENT DEVELOPMENTS
22.1.3 APOLLO HOSPITALS ENTERPRISE LTD.
22.1.3.1. COMPANY OVERVIEW
22.1.3.2. REVENUE ANALYSIS
22.1.3.3. GEOGRAPHIC PRESENCE
22.1.3.4. PRODUCT PORTFOLIO
22.1.3.5. RECENT DEVELOPMENTS
22.1.4 KOKILABEN DHIRUBHAI AMBANI HOSPITAL
22.1.4.1. COMPANY OVERVIEW
22.1.4.2. REVENUE ANALYSIS
22.1.4.3. GEOGRAPHIC PRESENCE
22.1.4.4. PRODUCT PORTFOLIO
22.1.4.5. RECENT DEVELOPMENTS
22.1.5 RIGSHOSPITALET
22.1.5.1. COMPANY OVERVIEW
22.1.5.2. REVENUE ANALYSIS
22.1.5.3. GEOGRAPHIC PRESENCE
22.1.5.4. PRODUCT PORTFOLIO
22.1.5.5. RECENT DEVELOPMENTS
22.1.6 THE UNIVERSITY OF IOWA.
22.1.6.1. COMPANY OVERVIEW
22.1.6.2. REVENUE ANALYSIS
22.1.6.3. GEOGRAPHIC PRESENCE
22.1.6.4. PRODUCT PORTFOLIO
22.1.6.5. RECENT DEVELOPMENTS
22.1.7 ADVENTIS ENT & COCHLEAR IMPLANT CLINIC
22.1.7.1. COMPANY OVERVIEW
22.1.7.2. REVENUE ANALYSIS
22.1.7.3. GEOGRAPHIC PRESENCE
22.1.7.4. PRODUCT PORTFOLIO
22.1.7.5. RECENT DEVELOPMENTS
22.1.8 BRISBANE HEADACHE AND MIGRAINE CLINIC
22.1.8.1. COMPANY OVERVIEW
22.1.8.2. REVENUE ANALYSIS
22.1.8.3. GEOGRAPHIC PRESENCE
22.1.8.4. PRODUCT PORTFOLIO
22.1.8.5. RECENT DEVELOPMENTS
22.1.9 THE ROYAL VICTORIAN EYE AND EAR HOSPITAL
22.1.9.1. COMPANY OVERVIEW
22.1.9.2. REVENUE ANALYSIS
22.1.9.3. GEOGRAPHIC PRESENCE
22.1.9.4. PRODUCT PORTFOLIO
22.1.9.5. RECENT DEVELOPMENTS
22.1.10 TRINITY HEARING & BALANCE
22.1.10.1. COMPANY OVERVIEW
22.1.10.2. REVENUE ANALYSIS
22.1.10.3. GEOGRAPHIC PRESENCE
22.1.10.4. PRODUCT PORTFOLIO
22.1.10.5. RECENT DEVELOPMENTS
22.1.11 DEENANATH MANGESHKAR HOSPITAL
22.1.11.1. COMPANY OVERVIEW
22.1.11.2. REVENUE ANALYSIS
22.1.11.3. GEOGRAPHIC PRESENCE
22.1.11.4. PRODUCT PORTFOLIO
22.1.11.5. RECENT DEVELOPEMENTS
22.1.12 HEARING HEALTH USA
22.1.12.1. COMPANY OVERVIEW
22.1.12.2. REVENUE ANALYSIS
22.1.12.3. GEOGRAPHIC PRESENCE
22.1.12.4. PRODUCT PORTFOLIO
22.1.12.5. RECENT DEVELOPMENTS
22.1.13 UNIVERSITY OF MARYLAND MEDICAL CENTER (UMMC)
22.1.13.1. COMPANY OVERVIEW
22.1.13.2. REVENUE ANALYSIS
22.1.13.3. GEOGRAPHIC PRESENCE
22.1.13.4. PRODUCT PORTFOLIO
22.1.13.5. RECENT DEVELOPMENTS
22.1.14 OAPC
22.1.14.1. COMPANY OVERVIEW
22.1.14.2. REVENUE ANALYSIS
22.1.14.3. GEOGRAPHIC PRESENCE
22.1.14.4. PRODUCT PORTFOLIO
22.1.14.5. RECENT DEVELOPMENTS
22.1.15 ENT SURGICAL CONSULTANTS, LTD
22.1.15.1. COMPANY OVERVIEW
22.1.15.2. REVENUE ANALYSIS
22.1.15.3. GEOGRAPHIC PRESENCE
22.1.15.4. PRODUCT PORTFOLIO
22.1.15.5. RECENT DEVELOPMENTS
22.1.16 HARTFORD HEALTHCARE
22.1.16.1. COMPANY OVERVIEW
22.1.16.2. REVENUE ANALYSIS
22.1.16.3. GEOGRAPHIC PRESENCE
22.1.16.4. PRODUCT PORTFOLIO
22.1.16.5. RECENT DEVELOPMENTS
22.1.17 ARNHEM PHYSIOTHERAPY SERVICES
22.1.17.1. COMPANY OVERVIEW
22.1.17.2. REVENUE ANALYSIS
22.1.17.3. GEOGRAPHIC PRESENCE
22.1.17.4. PRODUCT PORTFOLIO
22.1.17.5. RECENT DEVELOPMENTS
22.1.18 VIRINCHI HOSPITALS
22.1.18.1. COMPANY OVERVIEW
22.1.18.2. REVENUE ANALYSIS
22.1.18.3. GEOGRAPHIC PRESENCE
22.1.18.4. PRODUCT PORTFOLIO
22.1.18.5. RECENT DEVELOPMENTS
22.2 DRUG MANUFACTURERS
22.2.1 TAJ PHARMACEUTICALS LIMITED
22.2.1.1. COMPANY OVERVIEW
22.2.1.2. REVENUE ANALYSIS
22.2.1.3. GEOGRAPHIC PRESENCE
22.2.1.4. PRODUCT PORTFOLIO
22.2.1.5. RECENT DEVELOPEMENTS
22.2.2 ABBOTT
22.2.2.1. COMPANY OVERVIEW
22.2.2.2. REVENUE ANALYSIS
22.2.2.3. GEOGRAPHIC PRESENCE
22.2.2.4. PRODUCT PORTFOLIO
22.2.2.5. RECENT DEVELOPMENTS
22.2.3 AURIS MEDICAL
22.2.3.1. COMPANY OVERVIEW
22.2.3.2. REVENUE ANALYSIS
22.2.3.3. GEOGRAPHIC PRESENCE
22.2.3.4. PRODUCT PORTFOLIO
22.2.3.5. RECENT DEVELOPMENTS
22.2.4 WELLONA PHARMA
22.2.4.1. COMPANY OVERVIEW
22.2.4.2. REVENUE ANALYSIS
22.2.4.3. GEOGRAPHIC PRESENCE
22.2.4.4. PRODUCT PORTFOLIO
22.2.4.5. RECENT DEVELOPMENTS
22.2.5 ANI PHARMACEUTICALS, INC.
22.2.5.1. COMPANY OVERVIEW
22.2.5.2. REVENUE ANALYSIS
22.2.5.3. GEOGRAPHIC PRESENCE
22.2.5.4. PRODUCT PORTFOLIO
22.2.5.5. RECENT DEVELOPMENTS
22.2.6 AMNEAL PHARMACEUTICALS LLC.
22.2.6.1. COMPANY OVERVIEW
22.2.6.2. REVENUE ANALYSIS
22.2.6.3. GEOGRAPHIC PRESENCE
22.2.6.4. PRODUCT PORTFOLIO
22.2.6.5. RECENT DEVELOPMENTS
22.2.7 AKORN OPERATING COMPANY LLC
22.2.7.1. COMPANY OVERVIEW
22.2.7.2. REVENUE ANALYSIS
22.2.7.3. GEOGRAPHIC PRESENCE
22.2.7.4. PRODUCT PORTFOLIO
22.2.7.5. RECENT DEVELOPMENTS
22.2.8 TEVA UK LIMITE
22.2.8.1. COMPANY OVERVIEW
22.2.8.2. REVENUE ANALYSIS
22.2.8.3. GEOGRAPHIC PRESENCE
22.2.8.4. PRODUCT PORTFOLIO
22.2.8.5. RECENT DEVELOPMENTS
22.2.9 ZYDUS PHARMACEUTICALS
22.2.9.1. COMPANY OVERVIEW
22.2.9.2. REVENUE ANALYSIS
22.2.9.3. GEOGRAPHIC PRESENCE
22.2.9.4. PRODUCT PORTFOLIO
22.2.9.5. RECENT DEVELOPMENTS
22.2.10 TARO PHARMACEUTICAL INDUSTRIES LTD
22.2.10.1. COMPANY OVERVIEW
22.2.10.2. REVENUE ANALYSIS
22.2.10.3. GEOGRAPHIC PRESENCE
22.2.10.4. PRODUCT PORTFOLIO
22.2.10.5. RECENT DEVELOPMENTS
22.2.11 STRIDES PHARMA SCIENCE LIMITED
22.2.11.1. COMPANY OVERVIEW
22.2.11.2. REVENUE ANALYSIS
22.2.11.3. GEOGRAPHIC PRESENCE
22.2.11.4. PRODUCT PORTFOLIO
22.2.11.5. RECENT DEVELOPMENTS
22.2.12 MAYNE PHARMA GROUP LIMITED
22.2.12.1. COMPANY OVERVIEW
22.2.12.2. REVENUE ANALYSIS
22.2.12.3. GEOGRAPHIC PRESENCE
22.2.12.4. PRODUCT PORTFOLIO
22.2.12.5. RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23 RELATED REPORTS
24 CONCLUSION
25 QUESTIONNAIRE
26 ABOUT DATA BRIDGE MARKET RESEARCH
